Paper Details

  1. Home
  2. Paper Details

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.

Author: , AshcroftA John, BirdJenny M, BrownJulia M, CairnsDavid A, CavenaghJamie, CavetJim, ChalmersAnna, CookGordon, DraysonMark T, FletcherMarie, HunterHanna, MorrisTreen C M, O'ConnorSheila, ParrishChris, SnowdenJohn A, WilliamsCathy, YongKwee

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

High-dose melphalan plus salvage autologous stem-cell transplantation (ASCT) was significantly more effective than cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy. The median time to progression was significantly longer in the salvage ASCT group than in the cyclophosphamide group (19 months vs 11 months).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously under...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(14)70245-1

データ提供：米国国立医学図書館（NLM）

Salvage Autologous Stem-Cell Transplantation for Relapsed Multiple Myeloma

Multiple myeloma, a complex and challenging blood cancer, often requires intensive treatments. This study, conducted in a large, multicenter setting, investigates the effectiveness of high-dose melphalan followed by a salvage autologous stem-cell transplantation (ASCT) compared to cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT. Imagine this as a second chance at beating the disease, a courageous journey through the sandstorms of cancer. Researchers randomly assigned 174 eligible patients to receive either the high-dose melphalan/salvage ASCT regimen or cyclophosphamide. The study's primary outcome was the time to disease progression, and the results showed that the salvage ASCT group had a significantly longer time to progression than the cyclophosphamide group.

High-Dose Melphalan/Salvage ASCT: A Powerful Option for Relapsed Myeloma

The findings of this study provide strong evidence for the efficacy of high-dose melphalan/salvage ASCT as a treatment option for patients with relapsed multiple myeloma who are eligible for intensive therapy. This approach offers a potential lifeline for individuals battling this challenging disease. The study also reported several potential side effects associated with the treatments, including neutropenia, thrombocytopenia, and peripheral neuropathy.

Navigating the Challenges of Myeloma Treatment

The study's findings highlight the complex nature of multiple myeloma treatment. While high-dose melphalan/salvage ASCT appears to offer improved outcomes for some patients, it's essential to carefully weigh the potential benefits against the risks. Open communication with your healthcare provider is crucial for making informed decisions about treatment options and managing potential side effects.

Dr. Camel's Conclusion

Multiple myeloma treatment often involves navigating a treacherous landscape. This study presents a beacon of hope for those facing relapsed myeloma, highlighting the potential benefits of high-dose melphalan/salvage ASCT. While the journey may be challenging, with careful consideration and open communication with your healthcare team, you can find strength and resilience in the face of this disease.

Date :
  1. Date Completed 2014-09-09
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

24948586

DOI: Digital Object Identifier

10.1016/S1470-2045(14)70245-1

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.